Investigational drug · Phase 2
IMR-687
Also called: Tovinontrine, CRD-750
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure, Cardiovascular Diseases, Heart Diseases.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
7
Any phase or sponsor naming "IMR-687"
First trial start
2019
May 22, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMR-687", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure
- Cardiovascular Diseases
- Heart Diseases
- Sickle Cell Disease
- Heart Failure Preserved Ejection Fraction
- Heart Failure With Reduced Ejection Fraction
Approved drugs for the same conditions: Heart failure · Sickle cell disease · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "IMR-687" as an intervention, largest first.
- Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)Pivotal-lookingCompleted
Cardurion Pharmaceuticals, Inc.Industry
NCT06215586 · 303 participants · Start Feb 13, 2024 · Primary completion Sep 2, 2025
Drug: Tovinontrine (CRD-750); Placebo · For: Heart Failure; Heart Failure Preserved Ejection Fraction; Cardiovascular Diseases and 1 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Orange, California · 84 sites in all
- A Study of IMR-687 in Subjects With Beta ThalassemiaPivotal-lookingTerminated
Cardurion Pharmaceuticals, Inc.Industry
NCT04411082 · 122 participants · Start Oct 16, 2020 · Primary completion Mar 11, 2022
Drug: IMR-687; Placebo · For: β Thalassemia
Sites: Herlev, Denmark; Toulouse, France; Lyon, France · 36 sites in all
- A Study of IMR-687 in Subjects With Sickle Cell DiseasePivotal-lookingTerminated
Cardurion Pharmaceuticals, Inc.Industry
NCT04474314 · 115 participants · Start Aug 13, 2020 · Primary completion Mar 2, 2022
Drug: IMR-687; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 49 sites in all
- A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)Pivotal-lookingCompleted
Cardurion Pharmaceuticals, Inc.Industry
NCT03401112 · 100 participants · Start Jan 26, 2018 · Primary completion Aug 28, 2020
Drug: IMR-687; Placebo · For: Sickle Cell Disease
Sites: Oakland, California; Farmington, Connecticut; Hollywood, Florida · 13 sites in all
Cardurion Pharmaceuticals, Inc.Industry
NCT02998450 · 66 participants · Start Oct 18, 2016 · Primary completion Jul 8, 2017
Drug: IMR-687; Placebo Oral Capsule · For: Sickle Cell Disease; Sickle-Cell; Hb-SC; Sickle Beta 0 Thalassemia
Sites: Overland Park, Kansas
- An Extension Study of IMR-687 in Adult Patients With Sickle Cell AnemiaActive, not recruiting
Imara, Inc.Industry
NCT04053803 · 30 participants (planned) · Start May 22, 2019 · Primary completion Mar 2025
Drug: IMR-687 · For: Sickle Cell Disease
Sites: Farmington, Connecticut; Hollywood, Florida; Temple, Texas · 7 sites in all
- Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection FractionWithdrawn
Cardurion Pharmaceuticals, Inc.Industry
NCT05312021 · 0 participants · Start Apr 2022 · Primary completion Sep 2023
Drug: IMR-687 · For: Heart Failure With Preserved Ejection Fraction
Newest research
PubMed records naming it or its code names, newest first.
- β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL, Esrick EB · Hematology Am Soc Hematol Educ Program 2021
- Novel Therapeutic Advances in β-Thalassemia.
Makis A, Voskaridou E, Papassotiriou I, et al. · Biology (Basel) 2021
- A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.
McArthur JG, Svenstrup N, Chen C, et al. · Haematologica 2020
Also in development for Heart Failure
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- IRP101meta-fluorobenzylguanidine, 18F-MFBGPhase 34 trials
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- HiCM-188 therapyPhase 32 trials
HELP Therapeutics Co., Ltd. · Heart Failure
- Qishen Yiqi Dripping Pills 2 bagsPhase 32 trials
Tasly Pharmaceutical Group Co., Ltd · Heart Failure, Chronic Heart Failure With Preserved Ejection Fraction
- CDR132LPhase 22 trials
Novo Nordisk · Heart Failure
- AZD3427Phase 21 trial
AstraZeneca · Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.